ECE2017 Eposter Presentations: Reproductive Endocrinology Bone & Osteoporosis (1 abstracts)
Effects of male hypogonadism treatment on the bone mineral density
Mário Rui Mascarenhas 1, , Ana Paula Barbosa 1, , Ana Raquel Coelho Gomes 2 , Catarina Silvestre 2 , David Barbosa 2 , Raquel Paixão 2 , Carolina Faria 2 , Ana Sofia Osório 2 , Vânia Gomes 2 , Joana Ferreira 1 , Manuel Bicho 1 & Maria João Bugalho 2
1Endocrinology and Metabolic Diseases, Faculty Medicine of Lisbon, Lisbon, Portugal; 2Endocrinology, Diabetes and Metabolism Department, Santa University Maria Hospital-Chln, Epe, Lisbon, Portugal.
Increased recognition of the morbidity and mortality due to osteoporosis in men are main issues of public health. Ageing and the propensity to falls are the main risk factors for osteoporotic fractures in men; moreover, hypogonadism is an important secondary cause of low bone mineral density (BMD), but very little is known about the effect of hypogonadism treatment on the BMD.
Objective: The aim was to study the impact on BMD of the treatment of male hypogonadism.
Material and methods: A group of 26 men were devided in the hypogonadotrophic hypogonadism (n=17) and hypergonadotrophic hypogonadism (n=9) groups. The BMD at several skeletal sites (assessed by DXA scans) was evaluated before and during treatment (duration from 1 to 8 years, on average 3.1 (±2.3) years). Adequate statistical tests were used (statistical significance P<0.05).
Results: The treatment did not improved significantly the mean BMDs at several skeletal sites (Table 1). Moreover the BMDs were similar before and during the treatment in the hypergonadotrophic hypogonadism group; nevertheless, in the hypogonadotrophic hypogonadism group the mean BMDs were significantly higher at the lumbar spine, at the hip, at the forearm and at the whole body during therapy.
Conclusions: After more than three years of treatment there was no improvement on the BMD significantly in the total hypogonism group. The treatment of male hypogonadism has improved the BMD at several skeletal regions just in the hyponadotrophic group.
| BMD | Hypogonadism before treatment n=26 (100%) | Hypogonadism during treatment n=26 (100%) |
| Normal | 6 (23.1%) | 8 (30.8%) |
| Reduced | 12 (46.1%) | 11 (42.3%) |
| Osteoporosis | 8 (30.8%) | 7 (26.9%) |
Volume 49
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more